Dr Belinda Parker, A/Prof Phil Darcy
La Trobe University
What is the project?
This project explores the importance of an immune pathway in response to current and emerging breast cancer therapies. The results may lead to individualised treatment for patients with triple negative breast cancers.
What are you trying to achieve?
There are currently limited treatment options for patients with triple negative breast cancer (TNBC). We have found that specific immune pathways are lost in TNBC, possibly promoting an immune suppressed environment. Importantly, TNBC patients that have intact immune signals have a much better prognosis. We aim to test the potential of specific immune regulators as prognostic markers and markers of response to conventional and immune targeted therapies in TNBC.
Cancer Council Victoria Research Grant